MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jendso/bvag217

Медицинская библиотека · Journal of the Endocrine Society · 2026

Health utility, work productivity, and total economic burden of polycystic ovary syndrome.

Amiri Mina, Huang Yucheng, Thai Linda, Ottey Sasha, Patterson William, Delau Olivia R, Yadav Surabhi, Soucie Kendall, Partridge Ty, Buyalos Richard P, Azziz Ricardo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Polycystic ovary syndrome (PCOS), also known as polyendocrine metabolic ovarian syndrome (PMOS), impairs health-related quality of life (QoL) and daily functioning. While estimates of medical-related costs have been made, this study aimed to estimate indirect (work productivity-related) and intangible (QoL-related) economic costs.

METHODS

In a cross-sectional US registry (PCOS/PMOS = 433, controls = 252), we measured willingness to pay, health utility using the EuroQol five-dimension five-level (EQ-5D-5L) and the Short Form 6-Dimensions (SF-6D) tools, and work productivity with Work Productivity and Activity Impairment: General Health. Adjusted regression estimated utility differences were converted to quality-adjusted life year (QALY) loss. XGBoost classification with Shapley Additive exPlanations feature importance identified key discriminating domains.

RESULTS

PCOS/PMOS had lower health utility compared to controls (EQ-5D-5L, 0.72 vs 0.88; SF-6D, 0.67 vs 0.72; P < .001), corresponding to QALY losses of 0.12 and 0.04, respectively. Annual intangible costs per woman were then estimated to be $12 000 (per EQ-5D-5L) or $4000 (per SF-6D). Median work productivity loss for PCOS/PMOS was 39.5% vs 6.0% for controls (using $37/hour and 2080 hours/year). Considering the number of women with PCOS/PMOS in the United States, the total yearly indirect cost was estimated to be $97.9 billion, and yearly intangible cost was estimated to range from $17.8 billion (by SF-6D) to $53.4 billion (by EQ-5D-5L), in 2026 USD. Machine learning identified pain, anxiety/depression, and physical functioning limitations as key discriminators.

CONCLUSION

PCOS/PMOS is associated with lower utility, significant QALY losses, and work productivity impairment. Considering prior estimates of medical-related costs, the total annual US Societal burden ranges from $133 to $169 billion, predominantly from indirect and intangible costs, underscoring the profound functional and economic impact of the disorder.

Для цитирования: Amiri Mina, Huang Yucheng, Thai Linda, Ottey Sasha, Patterson William, Delau Olivia R, Yadav Surabhi, Soucie Kendall, Partridge Ty, Buyalos Richard P, Azziz Ricardo. Health utility, work productivity, and total economic burden of polycystic ovary syndrome.. Journal of the Endocrine Society. 2026. DOI: 10.1210/jendso/bvag217.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.